Meda Pharmaceuticals Inc. is the U.S. subsidiary of Meda AB.
The Meda Pharmaceutical product portfolio is focused primarily on respiratory, allergy, central nervous system, gastroenterology, musculoskeletal, rheumatology, erectile dysfunction, and women's health products.
Latest News
May 2, 2012:
Dymista approved by the FDA »
March 5, 2012:
Positive results for Dymista in three clinical studies »
December 15, 2011:
Meda announces PDUFA timeline for Dymista »
May 2, 2012:
Dymista approved by the FDA »
March 5, 2012:
Positive results for Dymista in three clinical studies »
December 15, 2011:
Meda announces PDUFA timeline for Dymista »
Independent Education Grants
Meda Pharmaceuticals Inc. supports bona fide educational programs through the provision of educational grants.
Meda Pharmaceuticals Inc. supports bona fide educational programs through the provision of educational grants.










